Oligonucleotide treatment of RAS-induced tumors in nude mice

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 18, Issue 1, 2001, Pages 35-55

  Wickstrom, E ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Antisense; Bladder cancer; DNA therapeutics; Genetic therapy; Oncogenes; Pancreatic cancer; Tumors

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID DERIVATIVE;

BLADDER CANCER; CARCINOGENESIS; CELL TRANSFORMATION; GENE SEQUENCE; GENE THERAPY; NONHUMAN; NUDE MOUSE; ONCOGENE RAS; PANCREAS CANCER; REVIEW; SOLID TUMOR; TUMOR GROWTH;

3T3 CELLS; 5' UNTRANSLATED REGIONS; ANIMALS; CELL DIVISION; CELL LINE, TRANSFORMED; CODON; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENES, RAS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES, ANTISENSE; RAS PROTEINS; RNA, MESSENGER; THERMODYNAMICS; TIME FACTORS; TUMOR CELLS, CULTURED;

ANIMALIA; MUS MUSCULUS;

EID: 0034967677     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:18:1:35     Document Type: Review

References (77)

1. Molecular themes in oncogenesis
2. Function and regulation of ras
3. Identification of a nucleotide exchange-promoting activity for p21ras
4. Purification of ras GTPase activating protein from bovine brain
5. Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus
6. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
7. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy
8. Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors
9. Mutation of K-RAS protooncogene and loss of heterozygosity on 6q27 in serous and mucinous ovarian carcinomas
10. Prenylation-dependent association of Ki-Ras with microtubules. Evidence for a role in subcellular trafficking
11. Single-agent paclitaxel in the treatment of breast cancer: Phase I and II development
12. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton
13. Farnesyltransferase inhibitors: Antineoplastic mechanism and clinical prospects
14. Synthesis of ribonucleosides and diribonucleoside phosphates containing 2-chloroethylamine and nitrogen mustard residues
15. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide
16. HL60 cell proliferation inhibited by an anti-c-myc pentadecadeoxynucleotide
17. Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA
18. Antisense Therapeutics
19. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma
20. First "antisense" drug will treat CMV retinitis
21. Anti-c-myc DNA increases differentiation and decreases colony formation by HL-60 cells
22. Daily addition of an anti-c-myc DNA oligomer induces granulocytic differentiation of human promyelocytic leukemia HL-60 cells in both serum-containing and serum-free media
23. Walking along human c-myc mRNA with antisense oligodeoxynucleotides: Maximum efficacy at the 5′ cap region
24. Complementary oligonucleotide probe of vesicular stomatitis virus matrix protein mRNA secondary structure
25. Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T24-transformed NIH3T3 cells
26. Antisense DNA downregulates protein kinase C isozymes (beta and alpha) and insulin-stimulated 2-deoxyglucose uptake in rat adipocytes
27. Non-sequence-specific inhibition of transferrin receptor expression in HL-60 leukemia cells by phosphorothioate oligodeoxynucleotides
28. Inhibition of HIV- 1 by deoxyribonucleotides directed against regulatory gene messages and response elements
29. Inhibition of rabies virus infection by an oligodeoxynucleotide complementary to rabies virus genomic RNA
30. Differential oligonucleotide activity in cell culture versus mouse models
31. Down-regulation of c-MYC antigen expression in lymphocytes of Emu-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates
32. Prevention of tumor formation in a mouse model of Burkitt's lymphoma by 6 weeks of treatment with anti-c-myc DNA phosphorothioate
33. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model
34. Preclinical antisense DNA therapy of cancer in mice
35. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice
36. Sequence specific inhibition of in vitro translation of mutated or normal ras p21
37. Modulation of ras expression by anti-sense, nonionic deoxyoligonucleotide analogs
38. Comparative inhibition of ras p21 protein synthesis with phosphorus-modified antisense oligonucleotides
39. Antisense inhibition of ras p21 expression that is sensitive to a point mutation
40. Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation
41. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity
42. Pharmacology of antisense therapeutic agents
43. Inhibition of anchorage-independent growth of ras-transformed cells on polyHEMA surface by antisense oligodeoxynucleotides directed against K-ras
44. Impact of oncogenes in tumor angiogenesis: Mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells
45. Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes
46. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo
47. Effects of two major activating lesions on the structure and conformation of human ras oncogene products
48. Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family
49. Polymer support oligonucleotide synthesis XVIII: Use of beta-cyanoethyl-N,N-dialkylamino-/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product
50. The automated synthesis of sulfur-containing oligodeoxyribonucleotides using 3H-1,2-benzodithiol-3-one 1,1-dioxide as a sulfur-transfer reagent
51. A rapid method for the purification of deprotected oligodeoxynucleotides
52. Tissue fractionation studies: Intracellular distribution patterns of enzymes in rat-liver tissue
53. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
54. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
55. Two types of target cells for transformation with avian myelocytomatosis virus
56. Nucleotide sequence analysis of the T24 human bladder carcinoma oncogene
57. Promoter region of the human Harvey ras proto-oncogene: Similarity to the EGF receptor proto-oncogene promoter
58. Nucleotide sequences of the mRNA's encoding the vesicular stomatitis virus G and M proteins determined from cDNA clones containing the complete coding regions
59. Nucleotide sequence analysis of a variant human T-cell leukemia virus (HTLV-Ib) provirus with a deletion in pX-I
60. Optimal computer folding of large RNA sequences using thermodynamics and auxiliary information
61. Establishment and characterization of four human bladder tumor cell lines and sublines with different degrees of malignancy
62. Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay
63. Metabolic turnover of human c-rasH p21 protein of EJ bladder carcinoma and its normal cellular and viral homologs
64. Oligonucleotides in cells and in organisms: Pharmacological considerations
65. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides
66. Studies on a calf thymus ribonuclease specific for ribonucleic acid-deoxyribonucleic acid hybrids
67. A pseudoknotted RNA oligonucleotide
68. Escherichia coli initiation factor IF3 binding to AUG and AUG-containing single strands and hairpin loops, and nonspecific binding to polymers
69. Initiation of translation in prokaryotes and eukaryotes
70. A fluorescence study of the binding of eucaryotic initiation factors to messenger RNA and messenger RNA analogues
71. Antisense oligonucleotides: Towards clinical trials
72. Regulatory considerations for oligonucleotide drugs: Updated recommendations for pharmacology and toxicology studies
73. Clinical studies of antisense therapy in cancer
74. Antisense therapy of hematologic malignancies